杜氏肌肉发育不良症中低血压的潜在治疗目标
Harshi Saxena1, Neal L Weintraub1, Yaoliang Tang1
1Vascular Biology Center, Department of Medicine, Medical College of Georgia at Augusta University, 1460 Laney Walker Blvd, Augusta, GA 30912, USA.
Medical hypotheses
|April 8, 2024
概括
杜氏肌肉发育不良 (DMD) 患者可能会因为血管中KCNQ5和RyR2基因表达增加而经历低血压. 针对这些通道可以为DMD提供新的低血压治疗方法.
科学领域:
- 心血管科学 心血管科学
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 杜氏肌肉发育不良 (DMD) 涉及影响心血管系统的DMD基因突变.
- 患有DMD的患者容易出现症状性低血压,但潜在的机制尚不清楚.
研究的目的:
- 为了研究杜氏肌肉发育不良症中低血压的遗传基础.
- 确定在DMD患者中管理低血压的潜在治疗点.
主要方法:
- 来自DMD突变小鼠的单细胞RNA测序数据的分析.
- 在血管光滑肌细胞中识别上调基因.
主要成果:
- 电压通道子家族Q成员5 (KCNQ5) 和氨酸受体2 (RyR2) 的表达在DMD小鼠中显著上调.
- 这些基因被确定为潜在的候选人,有助于DMD的低血压.
结论:
- 增加KCNQ5和RyR2的表达可能会导致DMD的动脉血压下降.
- 对KCNQ5和RyR2通道的药理抑制显示出对管理DMD相关的低血压有希望.
- 这项研究为改善杜氏肌肉发育不良患者的临床结果开辟了新的途径.
相关概念视频
Antihypertensive Drugs: Vasodilators
516
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
516
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Satellite Stem Cells and Muscular Dystrophy
2.0K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.0K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
156
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
156
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
160
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
160


